{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:15:07Z","timestamp":1768317307472,"version":"3.49.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Nasopharyngeal carcinoma (NPC) has an extremely high incidence rate in Southern China, resulting in a severe disease burden for the local population. Current EBV serologic screening is limited by false positives, and there is opportunity to integrate polygenic risk scores for personalized screening which may enhance cost-effectiveness and resource utilization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Markov model was developed based on epidemiological and genetic data specific to endemic areas of China, and further compared polygenic risk-stratified screening [subjects with a 10-year absolute risk (AR) greater than a threshold risk underwent EBV serological screening] to age-based screening (EBV serological screening for all subjects). For each initial screening age (30\u201334, 35\u201339, 40\u201344, 45\u201349, 50\u201354, 55\u201359, 60\u201364, and 65\u201369\u2009years), a modeled cohort of 100,000 participants was screened until age 69, and then followed until age 79.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among subjects aged 30 to 54\u2009years, polygenic risk-stratified screening strategies were more cost-effective than age-based screening strategies, and almost comprised the cost-effectiveness efficiency frontier. For men, screening strategies with a 1-year frequency and a 10-year absolute risk (AR) threshold of 0.7% or higher were cost-effective, with an incremental cost-effectiveness ratio (ICER) below the willingness to pay (\u00a5203,810, twice the local <jats:italic>per capita<\/jats:italic> GDP). Specifically, the strategies with a 10-year AR threshold of 0.7% or 0.8% are the most cost-effective strategies, with an ICER ranging from \u00a5159,752 to \u00a5201,738 compared to lower-cost non-dominated strategies on the cost-effectiveness frontiers. The optimal strategies have a higher probability (29.4\u201335.8%) of being cost-effective compared to other strategies on the frontier. Additionally, they reduce the need for nasopharyngoscopies by 5.1\u201327.7% compared to optimal age-based strategies. Likewise, for women aged 30\u201354\u2009years, the optimal strategy with a 0.3% threshold showed similar results. Among subjects aged 55 to 69\u2009years, age-based screening strategies were more cost-effective for men, while no screening may be preferred for women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our economic evaluation found that the polygenic risk-stratified screening could improve the cost-effectiveness among individuals aged 30\u201354, providing valuable guidance for NPC prevention and control policies in endemic areas of China.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2024.1375533","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T14:07:57Z","timestamp":1714658877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Polygenic risk-stratified screening for nasopharyngeal carcinoma in high-risk endemic areas of China: a cost-effectiveness study"],"prefix":"10.3389","volume":"12","author":[{"given":"Da-Wei","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Qiong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minzhong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Diao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Xia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Zhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Fen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fugui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingfang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Qiao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hua","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"ref1","volume-title":"Cancer Incidence in Five Continents, Vol. XI (electronic version)","author":"Bray","year":"2022"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2016.01.040","article-title":"Global trends in incidence and mortality of nasopharyngeal carcinoma","volume":"374","author":"Tang","year":"2016","journal-title":"Cancer Lett"},{"key":"ref5","article-title":"CCfDCaP MoHotPsRoC","volume-title":"Expert committee of project for early cancer diagnosis and treatment. Technical plan for cancer early diagnosis and treatment","year":"2011"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/jnci\/djad012","article-title":"Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions","volume":"115","author":"Lam","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/aje\/kws404","article-title":"Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in southern China","volume":"177","author":"Liu","year":"2013","journal-title":"Am J Epidemiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/annonc\/mdz231","article-title":"Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China","volume":"30","author":"Ji","year":"2019","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa011610","article-title":"Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men","volume":"345","author":"Chien","year":"2001","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat Rev Genet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"eaay9040","DOI":"10.1126\/science.aay9040","article-title":"Early detection of cancer","volume":"375","author":"Crosby","year":"2022","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","article-title":"Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations","volume":"50","author":"Khera","year":"2018","journal-title":"Nat Genet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41591-021-01549-6","article-title":"Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2018.1901","article-title":"Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast Cancer: a life-table model","volume":"4","author":"Pashayan","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/gim.2014.192","article-title":"Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis","volume":"17","author":"Pashayan","year":"2015","journal-title":"Genet Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e1002998","DOI":"10.1371\/journal.pmed.1002998","article-title":"Polygenic risk-tailored screening for prostate cancer: a benefit-harm and cost-effectiveness modelling study","volume":"16","author":"Callender","year":"2019","journal-title":"PLoS Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e2037657","DOI":"10.1001\/jamanetworkopen.2020.37657","article-title":"Benefit, harm, and cost-effectiveness associated with magnetic resonance imaging before biopsy in age-based and risk-stratified screening for prostate Cancer","volume":"4","author":"Callender","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A cost-effectiveness analysis of multigene testing for all patients with breast Cancer","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nrurol.2013.266","article-title":"The genetic epidemiology of prostate cancer and its clinical implications","volume":"11","author":"Eeles","year":"2014","journal-title":"Nat Rev Urol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature24284","article-title":"Association analysis identifies 65 new breast cancer risk loci","volume":"551","author":"Michailidou","year":"2017","journal-title":"Nature"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ijc.30447","article-title":"Estimation of heritability for nine common cancers using data from genome-wide association studies in Chinese population","volume":"140","author":"Dai","year":"2017","journal-title":"Int J Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/ng.601","article-title":"A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci","volume":"42","author":"Bei","year":"2010","journal-title":"Nat Genet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e1003103","DOI":"10.1371\/journal.pgen.1003103","article-title":"The principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove","volume":"8","author":"Tang","year":"2012","journal-title":"PLoS Genet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1093\/jnci\/djac177","article-title":"Whole-exome sequencing study of familial nasopharyngeal carcinoma and its implication for identifying high-risk individuals","volume":"114","author":"Wang","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1044579X02000871","article-title":"Familial nasopharyngeal carcinoma","volume":"12","author":"Zeng","year":"2002","journal-title":"Semin Cancer Biol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41467-022-29570-4","article-title":"A polygenic risk score for nasopharyngeal carcinoma shows potential for risk stratification and personalized screening","volume":"13","author":"He","year":"2022","journal-title":"Nat Commun"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","article-title":"Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis","volume":"8","author":"Zou","year":"2020","journal-title":"Lancet Glob Health"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41467-023-36374-7","article-title":"Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1002\/cncr.30775","article-title":"Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis from an endemic area","volume":"123","author":"Lv","year":"2017","journal-title":"Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-022-01625-6","article-title":"Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma","volume":"21","author":"Miller","year":"2022","journal-title":"Mol Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/jnci\/djaa198","article-title":"Cost-effectiveness of nasopharyngeal carcinoma screening with Epstein-Barr virus polymerase chain reaction or serology in high-incidence populations worldwide","volume":"113","author":"Miller","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7326\/M22-2216","article-title":"Risk model-based Lung Cancer screening: a cost-effectiveness analysis","volume":"176","author":"Toumazis","year":"2023","journal-title":"Ann Intern Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jama.1996.03540160061034","article-title":"Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine","volume":"276","author":"Siegel","year":"1996","journal-title":"JAMA"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12916-021-02076-4","article-title":"Liquid biopsy post-treatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1001\/jamaoncol.2021.4942","article-title":"Cost-effectiveness evaluation of the 2021 US preventive services task force recommendation for Lung Cancer screening","volume":"7","author":"Toumazis","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e2121403","DOI":"10.1001\/jamanetworkopen.2021.21403","article-title":"Estimated cost-effectiveness of endoscopic screening for upper gastrointestinal tract Cancer in high-risk areas in China","volume":"4","author":"Xia","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and non-genetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk tool-a web Interface for the prediction of breast and ovarian Cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-018-04109-8","article-title":"Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants","volume":"9","author":"Dadaev","year":"2018","journal-title":"Nature communications"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.gim.2022.04.020","article-title":"Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review","volume":"24","author":"Dixon","year":"2022","journal-title":"Genet Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/jmedgenet-2019-106763","article-title":"Understanding polygenic models, their development and the potential application of polygenic scores in healthcare","volume":"57","author":"Babb de Villiers","year":"2020","journal-title":"J Med Genet"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.eururo.2021.12.021","article-title":"Cost-effectiveness of the Stockholm3 test and magnetic resonance imaging in prostate Cancer screening: a microsimulation study","volume":"82","author":"Hao","year":"2022","journal-title":"Eur Urol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e0246674","DOI":"10.1371\/journal.pone.0246674","article-title":"The cost-effectiveness of prostate cancer screening using the Stockholm3 test","volume":"16","author":"Karlsson","year":"2021","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1093\/aje\/kwab155","article-title":"Clarifying the trade-offs of risk-stratified screening for prostate Cancer: a cost-effectiveness study","volume":"190","author":"Hendrix","year":"2021","journal-title":"Am J Epidemiol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1158\/1940-6207.CAPR-20-0620","article-title":"The costs and benefits of risk stratification for colorectal Cancer screening based on phenotypic and genetic risk: a health economic analysis","volume":"14","author":"Thomas","year":"2021","journal-title":"Cancer Prev Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12913-021-06396-2","article-title":"Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore","volume":"21","author":"Wong","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/0194599819832593","article-title":"Cost\u2010effectiveness of screening for nasopharyngeal carcinoma among Asian American men in the United States","volume":"161","author":"Harris","year":"2019","journal-title":"Surgery"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/sj.bjc.6603609","article-title":"Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma","volume":"96","author":"Ji","year":"2007","journal-title":"Br J Cancer"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.7150\/jca.23755","article-title":"Assessment of the long-term diagnostic performance of a new serological screening scheme in large-scale nasopharyngeal carcinoma screening","volume":"9","author":"Yu","year":"2018","journal-title":"J Cancer"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e003790","DOI":"10.1136\/jitc-2021-003790","article-title":"Efficacy, safety, and biomarker analysis of Camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study)","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"102361","DOI":"10.1016\/j.ctrv.2022.102361","article-title":"Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers","volume":"105","author":"Wong","year":"2022","journal-title":"Cancer Treat Rev"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1375533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T14:08:01Z","timestamp":1714658881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1375533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":52,"alternative-id":["10.3389\/fpubh.2024.1375533"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1375533","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"article-number":"1375533"}}